Day: March 24, 2025

Revenue up 28% to $12.9 million in 2024 Redomicile to U.S. Nears Completion; Set to Accelerate Market Opportunities Completed $10 Million Private Placement Entered into $50 Million At-The-Market (ATM) Program NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, today provided a business update and financial results for the year ended December 31, 2024. “The second half of 2024 was highlighted by commercial milestones, including a pivotal agreement with Maxar Intelligence granting them exclusive rights to task Satellogic’s high-revisit constellation and use our cost-effective satellite imagery to support national security missions for the U.S. Government and select U.S. partners internationally.” said Satellogic CEO, Emiliano Kargieman. “Additionally,...

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025 Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update. “2024 was a transformational year for Bolt as we focused the company on efficient development of the programs that could be most impactful for patients,” said Willie Quinn, Chief...

– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “We are excited to move ahead with our biosimilar development program for ABP-450...

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31,...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansionIRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. To be clear, this test kit is the assay that we expect can generate future material and self-sustaining revenue within...

Fourth Quarter Revenue Growth of 17% Led by Significant OEM GrowthDebt Restructuring and Concurrent Capital Raise Enhance Financial Position and LiquidityInitiates Corporate Optimization ProgramGuides to First Quarter 2025 Net Sales of Approximately $13.3 MillionTargets Positive Adjusted EBITDA in Fourth Quarter 2025 RENO, Nev., March 24, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial HighlightsNet sales of $12.2 million and $50.6 million OEM net sales of $6.2 million and $27.6 million Gross Margin of 20.8% and 23.0% Net Loss of $(9.8) million and...